WuXi Biologics guns for $500M Hong Kong IPO

The Chinese CRO WuXi Biologics has seen strong revenues in recent years.

The big China CRO WuXi Biologics is slated for an initial public offering of up to $513 million in Hong Kong.

According to Thomson Reuters, quoting anonymous people "close to the deal,” the booming contract research organization is said to be offering 193 million shares worth between HK$18.60 to HK$20.60 each, valuing the total deal at up to HK$3.98 billion ($513 million). WuXi has not commented on the reports.

Over a year ago, and a few months after taking the company private in a $3.3 billion deal, WuXi CEO Ge Li has was said to be looking to spin out its biologics unit in an IPO that would value the business at $1.5 billion, according to a report from Bloomberg.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Back in January, it posted new legal documents (PDF) confirming its IPO intentions, but with no financial or value details. It did, however, show strong revenue growth and a list of biopharma partners that include AstraZeneca, Roche, Tesaro and J&J.

Suggested Articles

Sumitovant CEO Myrtle Potter discusses the $3 billion Roivant-Sumitomo deal, her role at Sumitovant and what's up in 2020.

The FDA approved a new, tiny pacemaker from Medtronic that does not require the wiring of separate electrodes between the implant and the heart.

Antibiotics player Summit Therapeutics is gearing up for a new clinical trial of its lead asset, an antibiotic for Clostridium difficile infection.